GOOD
BUSINESS
Why Indian drugmakers are losing pricing power in the US

Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years
Read the original at Livemint ↗